This clinical trial is focused on studying a condition called myelofibrosis, which is a type of blood cancer that affects the bone marrow. The study is specifically looking at patients with primary myelofibrosis or those who have developed myelofibrosis after having other conditions like polycythemia vera or essential thrombocythemia. These patients have not responded well to a type of treatment known as Janus Kinase (JAK) inhibitors. The main goal of the study is to see how well a new treatment, called Navtemadlin (also known by its code name KRT-232), works in reducing the size of the spleen, an organ that can become enlarged in people with myelofibrosis.

Participants in the study will be randomly assigned to receive either Navtemadlin or the best available therapy, which is the most effective treatment currently available for their condition. The study will last for several weeks, and during this time, doctors will monitor the size of the spleen using imaging techniques like magnetic resonance imaging (MRI) or computed tomography (CT) scans. The study will also look at other factors, such as the symptoms experienced by participants and their need for blood transfusions.

The study aims to provide valuable information about the effectiveness of Navtemadlin in treating myelofibrosis, especially for those who have not had success with JAK inhibitors. By comparing the new treatment with existing therapies, researchers hope to find better ways to manage this challenging condition. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on how the treatment affects their health.